JP2000505469A5 - - Google Patents

Download PDF

Info

Publication number
JP2000505469A5
JP2000505469A5 JP1997530671A JP53067197A JP2000505469A5 JP 2000505469 A5 JP2000505469 A5 JP 2000505469A5 JP 1997530671 A JP1997530671 A JP 1997530671A JP 53067197 A JP53067197 A JP 53067197A JP 2000505469 A5 JP2000505469 A5 JP 2000505469A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997530671A
Other languages
English (en)
Japanese (ja)
Other versions
JP4102440B2 (ja
JP2000505469A (ja
Filing date
Publication date
Priority claimed from FR9602472A external-priority patent/FR2745290B1/fr
Application filed filed Critical
Publication of JP2000505469A publication Critical patent/JP2000505469A/ja
Publication of JP2000505469A5 publication Critical patent/JP2000505469A5/ja
Application granted granted Critical
Publication of JP4102440B2 publication Critical patent/JP4102440B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP53067197A 1996-02-28 1997-02-27 新規なエリスロマイシン誘導体、それらの調製方法及びそれらの医薬品としての使用 Expired - Lifetime JP4102440B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9602472A FR2745290B1 (fr) 1996-02-28 1996-02-28 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR96/02472 1996-02-28
PCT/FR1997/000351 WO1997031929A1 (fr) 1996-02-28 1997-02-27 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Publications (3)

Publication Number Publication Date
JP2000505469A JP2000505469A (ja) 2000-05-09
JP2000505469A5 true JP2000505469A5 (enExample) 2004-11-25
JP4102440B2 JP4102440B2 (ja) 2008-06-18

Family

ID=9489659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53067197A Expired - Lifetime JP4102440B2 (ja) 1996-02-28 1997-02-27 新規なエリスロマイシン誘導体、それらの調製方法及びそれらの医薬品としての使用

Country Status (31)

Country Link
US (1) US6096714A (enExample)
EP (1) EP0885234B1 (enExample)
JP (1) JP4102440B2 (enExample)
KR (1) KR100486053B1 (enExample)
CN (1) CN1168734C (enExample)
AP (1) AP952A (enExample)
AR (1) AR005999A1 (enExample)
AT (1) ATE217633T1 (enExample)
AU (1) AU716204B2 (enExample)
BG (1) BG63207B1 (enExample)
BR (1) BR9707709B1 (enExample)
CZ (1) CZ293893B6 (enExample)
DE (1) DE69712610T2 (enExample)
DK (1) DK0885234T3 (enExample)
EA (1) EA001376B1 (enExample)
EE (1) EE9800265A (enExample)
ES (1) ES2176698T3 (enExample)
FR (1) FR2745290B1 (enExample)
HU (1) HU227567B1 (enExample)
IL (1) IL125622A (enExample)
NO (1) NO983955L (enExample)
NZ (1) NZ331600A (enExample)
OA (1) OA10845A (enExample)
PL (1) PL191736B1 (enExample)
PT (1) PT885234E (enExample)
SK (1) SK118498A3 (enExample)
TR (1) TR199801713T2 (enExample)
UA (1) UA58504C2 (enExample)
WO (1) WO1997031929A1 (enExample)
YU (1) YU37098A (enExample)
ZA (1) ZA971659B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514643A (ja) * 1997-10-29 2004-05-20 大正製薬株式会社 エリスロマイシンa誘導体
WO1999021869A1 (en) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Erythromycin a, 11,12-carbamate derivatives
FR2780977B1 (fr) * 1998-07-09 2000-09-01 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
JP4573925B2 (ja) * 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
FR2792637B1 (fr) * 1999-04-26 2001-06-01 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2781484B1 (fr) * 1998-07-21 2001-08-10 Hoechst Marion Roussel Inc Nouveaux derives de la 6-deoxy erythromycine, leur procede de preparation et leur application comme medicaments
DK1147121T3 (da) 1999-01-27 2004-04-13 Pfizer Prod Inc Ketolidantibiotika
EE200100613A (et) * 1999-05-24 2003-02-17 Pfizer Products Inc. 13-metüülerütromütsiini derivaadid
AU6183800A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
WO2001010878A1 (fr) * 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
AU6316400A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
EP1146051A3 (en) * 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A derivatives
US20020115621A1 (en) * 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
ITMI20021726A1 (it) * 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
WO2005007143A2 (en) * 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
HRP20160168T1 (hr) 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba
BR112012029586A2 (pt) 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487411A (en) * 1892-12-06 Island
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5444031A (en) * 1993-01-21 1995-08-22 Calgon Carbon Corporation Process for making catalytic carbon
FR2727969B1 (fr) * 1994-12-09 1997-01-17 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Similar Documents

Publication Publication Date Title
JP2000506993A5 (enExample)
JP2000512519A5 (enExample)
JP2000508224A5 (enExample)
JP2001501399A5 (enExample)
JP2000510716A5 (enExample)
JP2000506627A5 (enExample)
JP2002505019A5 (enExample)
JP2000503005A5 (enExample)
JP2001525822A5 (enExample)
JP2000509445A5 (enExample)
JP2000516522A5 (enExample)
JP2000504881A5 (enExample)
JP2001501449A5 (enExample)
JP2002512644A5 (enExample)
JP2001500472A5 (enExample)
JP2001506986A5 (enExample)
JP2000506901A5 (enExample)
JP2001508367A5 (enExample)
JP2000505488A5 (enExample)
JP2001501133A5 (enExample)
JP2000515107A5 (enExample)
JP2001503005A5 (enExample)
JP2000504635A5 (enExample)
JP2001503400A5 (enExample)
JP2001506378A5 (enExample)